Bacil Pharma Ltd — Important, 18-07-2026: Company Update

The company's board approved a Rights Issue to raise up to 50 Cr. To enable this, the board also approved increasing the Authorised Share Capital by 45 Cr, bringing the new total to 65 Cr, pending shareholder approval. Intermediaries for the Rights Issue were appointed. Separately, two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, resigned from the board. A Right Issue Committee was formed, and the trading window for securities remains closed.